Predictors of Pulmonary Hypertension Risk in Premature Infants With Bronchopulmonary Dysplasia
| Status: | Recruiting |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), Hematology |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Hematology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 5/3/2018 |
| Start Date: | July 2011 |
| End Date: | January 2019 |
| Contact: | Christine Johnson, MD |
| Email: | clcjohns@stanford.edu |
| Phone: | 650 723-5711 |
Endothelin-1 (ET-1) Levels as Predictors of Pulmonary Hypertension Risk in Premature Infants With Bronchopulmonary Dysplasia (BPD)
A lung condition called bronchopulmonary dysplasia (BPD) is a major cause of poor outcomes
and death for premature infants. Infants with BPD are also at high risk for pulmonary
hypertension (PH)—an important contributor to their condition. Previous research has
suggested that a protein in the blood, endothelin-1 (ET-1), is associated with pulmonary
disease.
This study aims to investigate the incidence of PH and levels of ET-1 among premature babies
with BPD. It will also potentially allow us to focus further research efforts and treatment
towards these infants, some of our sickest patients at LPCH.
and death for premature infants. Infants with BPD are also at high risk for pulmonary
hypertension (PH)—an important contributor to their condition. Previous research has
suggested that a protein in the blood, endothelin-1 (ET-1), is associated with pulmonary
disease.
This study aims to investigate the incidence of PH and levels of ET-1 among premature babies
with BPD. It will also potentially allow us to focus further research efforts and treatment
towards these infants, some of our sickest patients at LPCH.
This study aims to 1) investigate the incidence of PH among premature infants with BPD versus
those without BPD and 2) investigate ET-1 levels in infants with BPD-associated PH versus
those without BPD-associated PH. This study will allow us to help define a high-risk
population at LPCH—namely, premature infants with BPD-associated PH. It will also potentially
allow us to focus further research efforts and treatment targets towards these infants who
encompass some of our sickest patients at LPCH.
In 2009 the Division of Lung Diseases of the National Heart, Lung and Blood Institute (NHLBI)
published seven priority areas for research in pediatric pulmonary diseases, one of which was
pulmonary vascular disease. An emphasis was made on finding 'clinical strategies that
anticipate the development of PH [which] may allow earlier recognition and more aggressive
therapy, thereby slowing the development of PH in many chronic lung parenchymal and vascular
diseases'. This study attempts to address this goal. Specifically we aim to evaluate ET-1
levels in premature infants diagnosed with BPD and with BPD-associated PH. If ET-1 levels are
found to correlate with disease state the possibility of prediction and possible early
treatment for PH in these infants is raised and merits investigation.
those without BPD and 2) investigate ET-1 levels in infants with BPD-associated PH versus
those without BPD-associated PH. This study will allow us to help define a high-risk
population at LPCH—namely, premature infants with BPD-associated PH. It will also potentially
allow us to focus further research efforts and treatment targets towards these infants who
encompass some of our sickest patients at LPCH.
In 2009 the Division of Lung Diseases of the National Heart, Lung and Blood Institute (NHLBI)
published seven priority areas for research in pediatric pulmonary diseases, one of which was
pulmonary vascular disease. An emphasis was made on finding 'clinical strategies that
anticipate the development of PH [which] may allow earlier recognition and more aggressive
therapy, thereby slowing the development of PH in many chronic lung parenchymal and vascular
diseases'. This study attempts to address this goal. Specifically we aim to evaluate ET-1
levels in premature infants diagnosed with BPD and with BPD-associated PH. If ET-1 levels are
found to correlate with disease state the possibility of prediction and possible early
treatment for PH in these infants is raised and merits investigation.
Inclusion Criteria:
- Premature Infants (<30 weeks EGA)
Exclusion Criteria:
- Major congenital malformations (cardiac, respiratory, gastrointestinal)
- congenital infection, and/or
- known genetic syndromes (i.e. trisomy 21)
We found this trial at
2
sites
Click here to add this to my saved trials
2500 Grant Rd
Mountain View, California 94040
Mountain View, California 94040
(650) 940-7000
Principal Investigator: Christine L Johnson, MD
El Camino Hospital El Camino Hospital is a nonprofit organization with hospital campuses in Mountain...
Click here to add this to my saved trials